AU2013302526B2 - Exosome-based therapeutics against neurodegenerative disorders - Google Patents

Exosome-based therapeutics against neurodegenerative disorders Download PDF

Info

Publication number
AU2013302526B2
AU2013302526B2 AU2013302526A AU2013302526A AU2013302526B2 AU 2013302526 B2 AU2013302526 B2 AU 2013302526B2 AU 2013302526 A AU2013302526 A AU 2013302526A AU 2013302526 A AU2013302526 A AU 2013302526A AU 2013302526 B2 AU2013302526 B2 AU 2013302526B2
Authority
AU
Australia
Prior art keywords
mir
exosomes
cells
pct
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013302526A
Other languages
English (en)
Other versions
AU2013302526A1 (en
Inventor
Yelena Y. Grinberg
Richard P. Kraig
Aya D. Pusic
Kae M. Pusic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of AU2013302526A1 publication Critical patent/AU2013302526A1/en
Application granted granted Critical
Publication of AU2013302526B2 publication Critical patent/AU2013302526B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
AU2013302526A 2012-08-15 2013-08-15 Exosome-based therapeutics against neurodegenerative disorders Active AU2013302526B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683596P 2012-08-15 2012-08-15
US61/683,596 2012-08-15
PCT/US2013/055187 WO2014028763A1 (en) 2012-08-15 2013-08-15 Exosome-based therapeutics against neurodegenerative disorders

Publications (2)

Publication Number Publication Date
AU2013302526A1 AU2013302526A1 (en) 2015-04-02
AU2013302526B2 true AU2013302526B2 (en) 2018-03-22

Family

ID=50101510

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013302526A Active AU2013302526B2 (en) 2012-08-15 2013-08-15 Exosome-based therapeutics against neurodegenerative disorders

Country Status (6)

Country Link
US (2) US10231997B2 (enExample)
EP (1) EP2885414B1 (enExample)
JP (1) JP2015524849A (enExample)
AU (1) AU2013302526B2 (enExample)
CA (1) CA2882248A1 (enExample)
WO (1) WO2014028763A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013302526B2 (en) 2012-08-15 2018-03-22 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US9958460B2 (en) * 2013-10-24 2018-05-01 Nanosomix, Inc. Biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
DK3145493T3 (da) * 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
WO2015179875A1 (en) * 2014-05-23 2015-11-26 Georgetown University Exosome and lipid biomarkers for memory loss
HK1247104A1 (zh) * 2015-01-05 2018-09-21 株式会社露太利温 使用luterion抑制癌细胞中端粒酶的方法
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
NZ742327A (en) * 2015-11-18 2020-01-31 Aruna Biomedical Inc Neural cell extracellular vessicles
EP3377043A4 (en) 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
US11243215B2 (en) 2016-01-14 2022-02-08 The Regents Of The University Of California 3D-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
CN109152737B (zh) 2016-03-02 2024-07-12 高等教育联邦系统-匹兹堡大学 结合基质的纳米囊泡及其用途
EP3423070B1 (en) * 2016-03-03 2022-05-04 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
EP4091622A1 (en) * 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
EP3500244B1 (en) 2016-08-22 2026-07-08 Lonza Sales AG Methods of suppressing delivery of exosomes to liver and spleen
US20200046766A1 (en) 2016-10-13 2020-02-13 Vbc Holdings Llc Cancer stem cell exosomes
AU2017354272A1 (en) 2016-11-03 2019-05-23 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018098312A2 (en) * 2016-11-23 2018-05-31 Mayo Foundation For Medical Education And Research Particle-mediated delivery of biologics
WO2018132728A1 (en) * 2017-01-12 2018-07-19 Duke University Compositions and methods for the treatment of demyelinating conditions
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
CN110662532A (zh) 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
WO2018208971A1 (en) * 2017-05-10 2018-11-15 University Of Louisville Research Foundation, Inc. Compositions comprising engineered embryonic stem cell-derived exosomes and method of use therefor
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
CN108103026B (zh) * 2017-12-05 2020-12-22 四川省肿瘤医院 用于肿瘤免疫治疗的γδ-T细胞外泌体及其制备方法
CN107988153B (zh) * 2017-12-15 2021-05-18 英科博雅生命科技有限公司 人脐带血间充质干细胞源分离外泌体的方法和使用的试剂
WO2019136268A1 (en) * 2018-01-05 2019-07-11 Mayo Foundation For Medical Education And Research Modulation of extracellular vesicles with electrical stimulation
WO2019217091A1 (en) 2018-04-30 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosomes and uses thereof
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US20200108241A1 (en) * 2018-10-04 2020-04-09 Synaptec Network, Inc. Systems and Methods for Delivering Exosomes Through the Blood-Brain Barrier
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
EP3920950A1 (en) 2019-02-08 2021-12-15 CureVac AG Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
CA3142487A1 (en) * 2019-06-04 2020-12-10 Thomas Jefferson University Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
JP7372518B2 (ja) * 2019-06-27 2023-11-01 国立大学法人山口大学 骨髄由来間葉系幹細胞の培養方法
US20220241325A1 (en) * 2019-07-26 2022-08-04 Mayo Foundation For Medical Education And Research Antioxidant and antiviral compositions and methods
CN111117964B (zh) * 2019-07-30 2020-12-01 段海峰 一种肿瘤来源外泌体及其制备方法和用途
TR201911667A2 (tr) * 2019-08-01 2021-02-22 Univ Yeditepe Hücrelerde oluşan protein birikintilerinden kaynaklanan hastalıkların tedavisi için kullanılan bitki eksozomları.
AU2020351220A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
JP2022552408A (ja) * 2019-10-16 2022-12-15 ザ ジョンズ ホプキンス ユニバーシティ 神経障害の治療のための細胞外小胞系薬剤及び方法
CN112972702A (zh) * 2019-12-17 2021-06-18 南京大学 用于治疗耐药菌感染的外泌体制剂
PH12022551608A1 (en) * 2019-12-31 2023-10-16 Chase Therapeutics Corp Kinases as biomarkers for neurodegenerative conditions
JP7562682B2 (ja) * 2020-01-27 2024-10-07 マントラ バイオ，インコーポレイテッド キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用
US20240415780A1 (en) * 2020-03-21 2024-12-19 Florica Therapeutics, Inc. Neuronal diencephalon stem cells and exosomes thereof for the treatment and prevention of diseases
CN111876388A (zh) * 2020-07-24 2020-11-03 赛瑞诚(苏州)生物科技有限公司 一种骨和骨组织靶向外泌体及其制备方法和应用
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
US20220296645A1 (en) * 2021-03-22 2022-09-22 Spiritus Therapeutics, Inc. Diagnostic and therapeutic uses of compositions comprising purified, enriched potent exosomes containing disease-based and therapy based signature cargo
US20250090470A1 (en) * 2021-07-07 2025-03-20 University Of Florida Research Foundation, Incorporated Light-induced cellular production of immune functional extracellular vesicles
CN116098921A (zh) * 2021-11-10 2023-05-12 南京大学 一种具有哺乳动物大脑系统抗衰作用的生物制品及其制备方法和应用
CN116440168A (zh) * 2022-01-06 2023-07-18 南京大学 一种生物制品及其制备方法和其在制备抗衰延寿产品中的应用
CN115006427A (zh) * 2022-05-31 2022-09-06 尧舜泽生物医药(南京)有限公司 骨髓间充质干细胞外泌体在治疗帕金森病中的应用
CN120712096A (zh) * 2022-11-23 2025-09-26 ExoMed私人有限公司 使用源自幼小哺乳动物的细胞外囊泡预防或治疗年龄相关病状的方法
WO2024186630A1 (en) * 2023-03-03 2024-09-12 Henry Ford Health System Use of extracellular vesicles for the treatment of cancer
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110003008A1 (en) * 2008-02-22 2011-01-06 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
FR2788780B1 (fr) 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US7689196B2 (en) 2002-06-26 2010-03-30 Qualcomm Incorporated Timer-based sleep for terminals in wireless communication systems
EP1713900A4 (en) * 2004-01-27 2009-06-17 Compugen Ltd METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
GB2459228B (en) 2007-07-25 2012-06-20 Univ Louisville Res Found Exosome-associated microrna as a diagnostic marker
CA2735575A1 (en) * 2007-08-10 2009-02-19 Wayne State University Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
DK2734634T3 (da) 2011-07-22 2019-10-21 Univ Chicago Igf-1 til anvendelse til behandling af migræne
AU2013302526B2 (en) * 2012-08-15 2018-03-22 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110003008A1 (en) * 2008-02-22 2011-01-06 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. FITZNER ET AL, "Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis", JOURNAL OF CELL SCIENCE, GB, (20110201), vol. 124, no. 3, doi:10.1242/jcs.074088, ISSN 0021-9533, pages 447 - 458 *
FRUHBEIS, C ET AL., "Emerging Roles Of Exosomes In Neuron-Glia Communication", FRONTIERS IN PHYSIOLOGY., (2012), vol. 3, pages 1 - 5 *
MARIA ELDH ET AL, "Exosomes Communicate Protective Messages during Oxidative Stress; Possible Role of Exosomal Shuttle RNA", PLOS ONE, (20101217), vol. 5, no. 12, doi:10.1371/journal.pone.0015353, page e15353 *
OLGA BARCA-MAYO ET AL, "Fine-Tuning Oligodendrocyte Development by microRNAs", FRONTIERS IN NEUROSCIENCE, (20120101), vol. 6, doi:10.3389/fnins.2012.00013 *

Also Published As

Publication number Publication date
EP2885414B1 (en) 2020-09-23
US11369634B2 (en) 2022-06-28
JP2015524849A (ja) 2015-08-27
US10231997B2 (en) 2019-03-19
CA2882248A1 (en) 2014-02-20
EP2885414A4 (en) 2016-01-06
US20150216899A1 (en) 2015-08-06
WO2014028763A1 (en) 2014-02-20
AU2013302526A1 (en) 2015-04-02
US20190160097A1 (en) 2019-05-30
EP2885414A1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
US11369634B2 (en) Exosome-based therapeutics against neurodegenerative disorders
Wang et al. Mesenchymal stem cell-derived exosomes reduce A1 astrocytes via downregulation of phosphorylated NFκB P65 subunit in spinal cord injury
Li et al. Exosomes derived from miR-133b-modified mesenchymal stem cells promote recovery after spinal cord injury
Ma et al. Insulin-like growth factor-1 enhances neuroprotective effects of neural stem cell exosomes after spinal cord injury via an miR-219a-2-3p/YY1 mechanism
Pusic et al. Youth and environmental enrichment generate serum exosomes containing miR‐219 that promote CNS myelination
WO2018029656A2 (en) Methods for making and using therapeutic exosomes
US8962583B2 (en) Treatment of inflammatory diseases using miR-124
EP3102679B1 (en) Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
Jiang et al. Circular RNA-based therapy provides sustained and robust neuroprotection for retinal ganglion cells
JP2022524391A (ja) 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用
Zhang et al. Exosomes mediate an epithelial‐mesenchymal transition cascade in retinal pigment epithelial cells: Implications for proliferative vitreoretinopathy
Yang et al. Engineered exosome‐based senolytic therapy alleviates stroke by targeting p21+ CD86+ microglia
Liang et al. Small extracellular vesicles from hypoxia-preconditioned bone marrow mesenchymal stem cells attenuate spinal cord injury via miR-146a-5p-mediated regulation of macrophage polarization
Wan et al. Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo
Yamada et al. A nanocarrier system for the delivery of nucleic acids targeted to a pancreatic beta cell line
Li et al. Small RNA-big impact: exosomal miRNAs in mitochondrial dysfunction in various diseases
Xu et al. Oligodendrocyte progenitor cell-specific delivery of lipid nanoparticles loaded with Olig2 synthetically modified messenger RNA for ischemic stroke therapy
Yasuzaki et al. Localization of exogenous DNA to mitochondria in skeletal muscle following hydrodynamic limb vein injection
Chinnici et al. Small extracellular vesicles from human fetal dermal cells and their microRNA cargo: KEGG signaling pathways associated with angiogenesis and wound healing
Hibino et al. An effective approach to modulate mitochondrial function in murine primary macrophages by a mitochondria-targeted nanocapsule, MITO-Porter
Saleh et al. Therapeutic gene delivery by mesenchymal stem cell for brain ischemia damage: Focus on molecular mechanisms in ischemic stroke
Shehata et al. Effect of mesenchymal stem cells on induced skeletal muscle chemodenervation atrophy in adult male albino rats
Kim et al. Mesenchymal stem cell derived extracellular vesicles reverses neural aging via OSKM modulation
Fu et al. Comparative transcriptomic profiling reveals a role for Olig1 in promoting axon regeneration
WO2019191109A1 (en) Microrna inhibitors and their use in treating epiretinal membranes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)